ArticleNature cancer2024
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.
Erratum issuedAbstract read
In one paragraph
Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Nature communications · 2026Trial
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.Transfusion · 2026Article
- Mapping clinical CAR-T cells: insights from scRNA-seq.Trends in molecular medicine · 2026Review
- CAR T-cells in hematologic malignancies: Advances, challenges, and future directions.iScience · 2026Review
- Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy.Nature communications · 2026Article
- Label-free TIMING: an efficient, reliable and scalable AI workflow for automated profiling of cell-cell interaction behaviors in nanowell arrays.Frontiers in bioinformatics · 2026Article
- The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy.Frontiers in immunology · 2026Review
- Plying potency assays for immunotherapy of solid tumors.Frontiers in immunology · 2026Review
- T cell immunotherapy for solid tumors: limitations, progress, and future prospects.Frontiers in immunology · 2026Review
- Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy.Signal transduction and targeted therapy · 2025Article
- Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity.Blood advances · 2025Review
- TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength.Cancer immunology research · 2025Article
- Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.medRxiv : the preprint server for health sciences · 2025Article
- From Multi-Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR-T Cell Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- The Bidirectional Interplay between T Cell-Based Immunotherapies and the Tumor Microenvironment.Cancer immunology research · 2025Review
- Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.Scientific reports · 2025Article
- Action and therapeutic targets of folliculin interacting protein 1: a novel signaling mechanism in redox regulation.Frontiers in cell and developmental biology · 2025Review
- New insights on potency assays from recent advances and discoveries in CAR T-cell therapy.Frontiers in immunology · 2025Review
- CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies.Frontiers in immunology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
21 authors.
Ali RezvanDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Gabrielle RomainDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Mohsen FathiCellChorus, Houston, TX, USA.
Darren HeekeKite, a Gilead Company, Santa Monica, CA, USA.
Melisa Martinez-PaniaguaDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Xingyue AnDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9912-0683
Irfan N BandeyDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Melisa J MontalvoDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Jay R T AdolacionDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Arash SaeediDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Fatemeh SadeghiDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Kristen FousekTexas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
Nahum Puebla-OsorioDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6498-5230
Laurence J N CooperCellChorus, Houston, TX, USA.
Chantale BernatchezDepartment of Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Harjeet SinghDivsion of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6314-5790
Nabil AhmedTexas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
Mike MattieKite, a Gilead Company, Santa Monica, CA, USA.
Adrian BotKite, a Gilead Company, Santa Monica, CA, USA.
Sattva NeelapuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1045-4914
Navin VaradarajanDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA. nvaradar@central.uh.edu.ORCID http://orcid.org/0000-0001-7524-8228
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MVISION RESEARCH CENTERP30EY002520 · NEI · BAYLOR COLLEGE OF MEDICINE · PI Samuel M Wu · 1985 to 2026
$14.8MMusIC: A multi-scale technology for integrating dynamic cellular function and molecular profilesR01GM143243 · NIGMS · UNIVERSITY OF HOUSTON · PI VARADARAJAN, NAVIN · 2021 to 2024
$1.8MHigh Throughput Genomic Sequencer at BCM Core FacilityS10OD023469 · OD · BAYLOR COLLEGE OF MEDICINE · PI CHEN, RUI · 2017 to 2017
$600kAcquisition of the Fluidigm system to accelerate functional genomics researchS10OD018033 · OD · BAYLOR COLLEGE OF MEDICINE · PI CHEN, RUI · 2014 to 2014
$396kProstate Cancer Detection Through Urine Headspace Analysis Using Colorimetric SenR43CA180466 · NCI · ISENSE MEDICAL CORPORATION · PI RHODES, PAUL · 2014 to 2014
$150kAcquisition of 10X Genomics Chromium Instrument to Accelerate Genomic and Single Cell Transcriptomic ResearchS10OD025240 · OD · BAYLOR COLLEGE OF MEDICINE · PI DODDAPANENI, HARSHA VARDHAN · 2018 to 2018
$125kCancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP180466Melanoma Research Alliance (MRA) 509800National Science Foundation (NSF) 1705464NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NEI NIH HHS P30 EY002520NIGMS NIH HHS R01 GM143243NIH HHS S10 OD018033NIH HHS S10 OD023469NIH HHS S10 OD025240United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP) CA160591U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01GM143243
Abstract
Chimeric antigen receptor (CAR) T cells used for the treatment of B cell malignancies can identify T cell subsets with superior clinical activity. Here, using infusion products of individuals with large B cell lymphoma, we integrated functional profiling using timelapse imaging microscopy in nanowell grids with subcellular profiling and single-cell RNA sequencing to identify a signature of multifunctional CD8
Indexed as
CD8-Positive T-LymphocytesImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenSingle-Cell AnalysisBiological ProductsHumansT-Lymphocyte Subsetsaxicabtagene ciloleucelBiological ProductsReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.